# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Biren Amin initiates coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral rating and annou...
HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $92 p...
Rapid reduction in disease activity seen at 12 weeks was sustained at one year55% of patients showed zero C3c staining intensit...
Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Equal-Weight and lowers the price t...
Apellis received $375 million in funding at close, with ability to access an additional $100 millionMajority of initial proceed...
Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target f...
HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $92 p...